Table 2.
Studies assessing the impact of PSMA-PET/CT on salvage radiotherapy planning.
| Authors | Year | n | Median PSA (ng/ml) (range) | PSA limit (ng/ml) | PSMA+ | Extra-pelvic PSMA+ | Any SRT planning change |
|---|---|---|---|---|---|---|---|
| Van Leeuwen et al. (15) | 2016 | 70 | 0.2 (0.05–0.99) | <1 | 55% | 6% | 35% |
| Sterzing et al. (16) | 2016 | 42 | 2.8 (0.16–113) | None | 60% | N/A | 61% |
| Bluemel et al. (17) | 2016 | 45 | 0.67 (0.10–11.2) | None | 54% | 9% | 42% |
| Albisinni et al. (18) | 2017 | 48 | 2.2 (0.72–6.7) | None | N/A | N/A | 76% |
| Habl et al. (19) | 2017 | 83 | 0.69 (0.09–14.7) | None | 71% | 10% | 57% |
| Koerber et al. (20) | 2018 | 71 | 1.2 (0.03–41.24) | None | N/A | 51% | 54% |
| Frenzel et al. (21) | 2018 | 75 | 0.2 (0.02–653.2) | None | N/A | N/A | 43% |
| Farolfi et al. (11) | 2019 | 119 | 0.32 (0.20–0.50) | <0.5 | 35% | 21% | 30% |
| Calais et al. (22) | 2018 | 270 | 0.48 (0.03–1.0) | <1 | 49% | 13% | 19% |
| Schmidt-Hegemann et al. (23) | 2019 | 62 | 0.44 (0.15–6.24) | None | 54% | 3% | 50% |
| Boreta et al. (24) | 2019 | 125 | 0.4 (0.28–0.63) | ≤2.0 | 53% | 20% | 30% |
| Current study | 2020 | 76 | 0.25 (0.07–0.50) | <0.5 | 54% | 3% | 28% |
N/A, not available.